Literature DB >> 22059453

Caffeine is protective in patients with non-alcoholic fatty liver disease.

A Birerdinc1, M Stepanova, L Pawloski, Z M Younossi.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome, is the most common cause of primary liver disease. Although recent studies have found that coffee drinking is protective against end stage chronic liver disease, there are scarce caffeine intake data in NAFLD specifically. AIM: To investigate the effects of dietary behaviour in NAFLD patients, using four continuous cycles of the National Health and Nutrition Examination Surveys (NHANES 2001-2008).
METHODS: Using data from four continuous cycles of NHANES, dietary intake questionnaires that list 62 nutrition components. Logistic regression was used to identify independent predictors of NAFLD among nutrition components after adjustment for potential clinical confounders. All analyses were run using sas 9.1 and SUDAAN 10.0 (SAS Institute Inc., Cary, NC, USA).
RESULTS: Of the 62 nutrient components used for the univariate analysis, 38% were significant (P-value <0.05) in NAFLD with caffeine consumption being higher in the control group (P-value <0.001). The multivariate analysis using demographics, clinical parameters and nutritional components found five factors independently associated with NAFLD [African American Race P-value <0.001); Male gender P-value <0.001); Obesity (BMI ≥ 30) P-value <0.001); Caffeine intake (mg) P-value <0.001) and total plain water consumption (g) P-value ≤ 0.02)].
CONCLUSIONS: Our analysis shows that caffeine intake is independently associated with a lower risk for NAFLD suggesting a potential protective effect. These data necessitate further research to elucidate the mechanism by which caffeine can protect against NAFLD.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22059453     DOI: 10.1111/j.1365-2036.2011.04916.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  39 in total

Review 1.  Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

Authors:  Tannaz Eslamparast; Sareh Eghtesad; Hossein Poustchi; Azita Hekmatdoost
Journal:  World J Hepatol       Date:  2015-02-27

Review 2.  Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?

Authors:  Bülent Baran; Filiz Akyüz
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Autophagy and liver disease.

Authors:  Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2013-09-16

4.  Coffee and liver - long way to go.

Authors:  Ajay K Duseja
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

Review 5.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 6.  Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults.

Authors:  Elena S George; Adrienne Forsyth; Catherine Itsiopoulos; Amanda J Nicoll; Marno Ryan; Siddharth Sood; Stuart K Roberts; Audrey C Tierney
Journal:  Adv Nutr       Date:  2018-01-01       Impact factor: 8.701

Review 7.  Non-alcoholic fatty liver disease: what the clinician needs to know.

Authors:  Mariana Verdelho Machado; Helena Cortez-Pinto
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 8.  Coffee and Liver Disease.

Authors:  Manav Wadhawan; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2016-02-27

9.  Short-term effect of caffeine on olfactory function in hyposmic patients.

Authors:  Thomas Meusel; Janine Albinus; Antje Welge-Luessen; Antje Hähner; Thomas Hummel
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-07       Impact factor: 2.503

Review 10.  Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis.

Authors:  Huafeng Shen; Andrea C Rodriguez; Ashok Shiani; Seth Lipka; Ghulamullah Shahzad; Ambuj Kumar; Paul Mustacchia
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.